Compare Amphastar Pharmaceuticals Inc (AMPH) vs Halliburton Company (HAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Halliburton Company — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Halliburton Company trades at $33.61 (market cap $28.03B). The key difference: Halliburton Company is far larger — about 32.4× Amphastar Pharmaceuticals Inc's market cap, and Halliburton Company pays a 2.02% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | HAL | |
|---|---|---|
Market Cap | $863.95M | $28.03B |
Sector | Health | Energy |
52-Week High | $30.81 | $42.98 |
52-Week Low | $16.87 | $20.50 |
Enterprise Value | $1.26B | $34.18B |
Dividend Yield | — | 2.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Halliburton (HAL) trades at $31.89, down 1.91% amid technical bearish signals despite strong fundamentals. The company reported Q2 2026 EPS of $0.55, beating estimates, with revenue growth driven by international contracts. Valuation metrics remain attractive with P/E of 16.7 and P/S of 1.2, while analyst consensus shows 73% buy ratings with a $43.60 price target. Recent news highlights contract wins in Kuwait and Australia, though Middle East volatility presents near-term headwinds.
HAL offers value with solid earnings momentum and global expansion, but faces execution risks from geopolitical tensions and oil market volatility. The stock's current discount to analyst targets presents opportunity, though technical weakness suggests cautious entry timing. Long-term growth prospects remain intact through technology leadership and international contract pipeline.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Halliburton Company
Halliburton is one of the three largest oilfield service firms in the world, offering superior expertise in a number of business lines, including completion fluids, wireline services, cementing, and countless others. It's the number one pressure pumper in North America, and has been a leading innovator in hydraulic fracturing over the last two decades.
Read more on HAL →
